Offering the Appropriate Patient the Opportunity for Treatment with TRK InhibitorsVideo Categories: NTRK Gene Fusions
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, discuss who may and may not be appropriate candidates for TRK inhibitor therapy.
How International Standards for Molecular Biomarker Testing in Lung Cancer Have Influenced Which Tests are Routinely Performed
Drs. Roy Herbst and David Rimm discuss the 50-gene panel that has become an ISLC-mandated standard for all patients with lung cancer; however, the components of cancer biomarker testing panels must be fluid and respond to new developments in the field as reported in the literature and/or at international cancer [ Read More ]
Randy Vogenberg discusses the complexities of developing pricing for personalized medicine products